Phenotypic characteristics of CD133+EpCAM+ cancer stem-like cells derived from the human hepatoma HepG2 cell line

Background/aim Cancer stem-like cells (CSCs) have been found to be a serious hurdle in the effective treatment of cancer. The rationale of this study was to isolate and characterize CD133+EpCAM+-enriched cells from the human hepatoma HepG2 cell line to prove their stemness phenotype. Materials and m...

Full description

Bibliographic Details
Main Authors: Hadeer A. Aglan, Nadia S. Mahmoud, Manar A. Elhinnawi, Ahmed A. Abd-Rabou, Hanaa H. Ahmed
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2022-01-01
Series:Journal of the Arab Society for Medical Research
Subjects:
Online Access:http://www.new.asmr.eg.net/article.asp?issn=1687-4293;year=2022;volume=17;issue=1;spage=77;epage=88;aulast=Aglan
_version_ 1818194603458691072
author Hadeer A. Aglan
Nadia S. Mahmoud
Manar A. Elhinnawi
Ahmed A. Abd-Rabou
Hanaa H. Ahmed
author_facet Hadeer A. Aglan
Nadia S. Mahmoud
Manar A. Elhinnawi
Ahmed A. Abd-Rabou
Hanaa H. Ahmed
author_sort Hadeer A. Aglan
collection DOAJ
description Background/aim Cancer stem-like cells (CSCs) have been found to be a serious hurdle in the effective treatment of cancer. The rationale of this study was to isolate and characterize CD133+EpCAM+-enriched cells from the human hepatoma HepG2 cell line to prove their stemness phenotype. Materials and methods The CD133+EpCAM+ cells were sorted from the HepG2 cell line using magnetic cell sorting and specified by flow cytometry analysis of surface markers [CD13, CD24, CD34, CD44, CD90, CD133, and CD326 (EpCAM)] and transmission electron microscopy to confirm their identity as CSCs. Quantitative real-time PCR analysis was applied for determining the expression level of stemness marker genes: Oct4, Nanog, ALDH1A1, Notch receptors (NOTCH1, NOTCH2, and NOTCH3), and cytokeratins (CK8/18/19). The proliferative ability of the isolated cells was identified through MTT assay, and their sensitivity to chemotherapeutic drugs was measured by cell counting kit-8 assay. Results The isolated CD133+EpCAM+ cells from the HepG2 cell line characterized by flow cytometry were positive for CD13 (81.8%), CD24 (24.4%), CD34 (3.36%), CD44 (92.0%), CD90 (39.7%), CD133 (82.3%), and CD326 (2.79%). Moreover, our data clarified from transmission electron microscopy examination that the isolated CD133+EpCAM+ cells exhibited irregular cell morphology and integral cell membrane structure. The sorted CD133+EpCAM+ cells possessed considerable increase in the mRNA level of Oct4, Nanog, ALDH1A1, NOTCH1, NOTCH2, NOTCH3, and CK19 genes, whereas they showed significant decrease in the mRNA level of CK8 and CK18 genes versus CD133-EpCAM- cells. Moreover, starting from day 4 to day 10, the CD133+EpCAM+ cells showed a significant increase in their proliferation rate and displayed high resistance to chemotherapy (doxorubicin) contrary to CD133-EpCAM- cells. Conclusion On the basis of the aforementioned results, CD133+EpCAM+-enriched cells strictly represented CSC phenotype in the HepG2 cell line. These cells might be valuable for studying the mechanism of CSCs in hepatoma and screening novel targets for cancer therapy.
first_indexed 2024-12-12T01:04:55Z
format Article
id doaj.art-ef926dc60ecb4cac8e5ba77b65f76404
institution Directory Open Access Journal
issn 1687-4293
2090-3286
language English
last_indexed 2024-12-12T01:04:55Z
publishDate 2022-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of the Arab Society for Medical Research
spelling doaj.art-ef926dc60ecb4cac8e5ba77b65f764042022-12-22T00:43:36ZengWolters Kluwer Medknow PublicationsJournal of the Arab Society for Medical Research1687-42932090-32862022-01-01171778810.4103/jasmr.jasmr_4_22Phenotypic characteristics of CD133+EpCAM+ cancer stem-like cells derived from the human hepatoma HepG2 cell lineHadeer A. AglanNadia S. MahmoudManar A. ElhinnawiAhmed A. Abd-RabouHanaa H. AhmedBackground/aim Cancer stem-like cells (CSCs) have been found to be a serious hurdle in the effective treatment of cancer. The rationale of this study was to isolate and characterize CD133+EpCAM+-enriched cells from the human hepatoma HepG2 cell line to prove their stemness phenotype. Materials and methods The CD133+EpCAM+ cells were sorted from the HepG2 cell line using magnetic cell sorting and specified by flow cytometry analysis of surface markers [CD13, CD24, CD34, CD44, CD90, CD133, and CD326 (EpCAM)] and transmission electron microscopy to confirm their identity as CSCs. Quantitative real-time PCR analysis was applied for determining the expression level of stemness marker genes: Oct4, Nanog, ALDH1A1, Notch receptors (NOTCH1, NOTCH2, and NOTCH3), and cytokeratins (CK8/18/19). The proliferative ability of the isolated cells was identified through MTT assay, and their sensitivity to chemotherapeutic drugs was measured by cell counting kit-8 assay. Results The isolated CD133+EpCAM+ cells from the HepG2 cell line characterized by flow cytometry were positive for CD13 (81.8%), CD24 (24.4%), CD34 (3.36%), CD44 (92.0%), CD90 (39.7%), CD133 (82.3%), and CD326 (2.79%). Moreover, our data clarified from transmission electron microscopy examination that the isolated CD133+EpCAM+ cells exhibited irregular cell morphology and integral cell membrane structure. The sorted CD133+EpCAM+ cells possessed considerable increase in the mRNA level of Oct4, Nanog, ALDH1A1, NOTCH1, NOTCH2, NOTCH3, and CK19 genes, whereas they showed significant decrease in the mRNA level of CK8 and CK18 genes versus CD133-EpCAM- cells. Moreover, starting from day 4 to day 10, the CD133+EpCAM+ cells showed a significant increase in their proliferation rate and displayed high resistance to chemotherapy (doxorubicin) contrary to CD133-EpCAM- cells. Conclusion On the basis of the aforementioned results, CD133+EpCAM+-enriched cells strictly represented CSC phenotype in the HepG2 cell line. These cells might be valuable for studying the mechanism of CSCs in hepatoma and screening novel targets for cancer therapy.http://www.new.asmr.eg.net/article.asp?issn=1687-4293;year=2022;volume=17;issue=1;spage=77;epage=88;aulast=Aglancancer stem-like cellscd133epcamhepg2 cell linestemness markers
spellingShingle Hadeer A. Aglan
Nadia S. Mahmoud
Manar A. Elhinnawi
Ahmed A. Abd-Rabou
Hanaa H. Ahmed
Phenotypic characteristics of CD133+EpCAM+ cancer stem-like cells derived from the human hepatoma HepG2 cell line
Journal of the Arab Society for Medical Research
cancer stem-like cells
cd133
epcam
hepg2 cell line
stemness markers
title Phenotypic characteristics of CD133+EpCAM+ cancer stem-like cells derived from the human hepatoma HepG2 cell line
title_full Phenotypic characteristics of CD133+EpCAM+ cancer stem-like cells derived from the human hepatoma HepG2 cell line
title_fullStr Phenotypic characteristics of CD133+EpCAM+ cancer stem-like cells derived from the human hepatoma HepG2 cell line
title_full_unstemmed Phenotypic characteristics of CD133+EpCAM+ cancer stem-like cells derived from the human hepatoma HepG2 cell line
title_short Phenotypic characteristics of CD133+EpCAM+ cancer stem-like cells derived from the human hepatoma HepG2 cell line
title_sort phenotypic characteristics of cd133 epcam cancer stem like cells derived from the human hepatoma hepg2 cell line
topic cancer stem-like cells
cd133
epcam
hepg2 cell line
stemness markers
url http://www.new.asmr.eg.net/article.asp?issn=1687-4293;year=2022;volume=17;issue=1;spage=77;epage=88;aulast=Aglan
work_keys_str_mv AT hadeeraaglan phenotypiccharacteristicsofcd133epcamcancerstemlikecellsderivedfromthehumanhepatomahepg2cellline
AT nadiasmahmoud phenotypiccharacteristicsofcd133epcamcancerstemlikecellsderivedfromthehumanhepatomahepg2cellline
AT manaraelhinnawi phenotypiccharacteristicsofcd133epcamcancerstemlikecellsderivedfromthehumanhepatomahepg2cellline
AT ahmedaabdrabou phenotypiccharacteristicsofcd133epcamcancerstemlikecellsderivedfromthehumanhepatomahepg2cellline
AT hanaahahmed phenotypiccharacteristicsofcd133epcamcancerstemlikecellsderivedfromthehumanhepatomahepg2cellline